Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management

6533b85bfe1ef96bd12bad5c

RESEARCH PRODUCT

Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management

Vivekanand Jha Vivekanand Jha Nassim Kamar Nassim Kamar José M. Morales Ching-lung Lai Craig E. Gordon Jacques Izopet Stanislas Pol Mengyang Di Paul J. Martin Marcelo Silva Amy Earley Wahid Doss Bertram L. Kasiske Michel Jadoul Ethan M Balk Fabrizio Fabrizi Priti R. Patel Marina Berenguer

subject

Liver Cirrhosis hepatitis C virus medicine.medical_treatment 030232 urology & nephrology lcsh:RC870-923 medicine.disease_cause cryoglobulinemia liver testing antivirals 0302 clinical medicine systematic review Medicine Infection control Kidney transplantation KDIGO Cross Infection hemodialysis nosocomial transmission virus diseases Hepatitis C Hepatitis C infection control Nephrology Practice Guidelines as Topic 030211 gastroenterology & hepatology Hemodialysis guideline Glomerular Filtration Rate medicine.medical_specialty Hepatitis C virus kidney transplantation Antiviral Agents 03 medical and health sciences Renal Dialysis Disease Transmission Infectious Humans Renal Insufficiency Chronic Intensive care medicine glomerular diseases direct-acting antivirals Dialysis business.industry screening Guideline lcsh:Diseases of the genitourinary system. Urology medicine.disease Kidney Transplantation dialysis business chronic kidney disease Kidney disease

description

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.

year	journal	country	edition	language
2018-10-01	Kidney International

https://doi.org/10.1016/j.kint.2018.06.011